Provista Life Sciences LLC (PLS) announced today that the National Health System’s Ethical Committee approval has been granted to proceed with a validation study of its Biomarker Translation Test (BT Test) in the United Kingdom (UK). The BT Test, a new blood test developed by Provista Life Sciences to aid healthcare providers in early breast […]
CENTER VALLEY, Pa. November 11, 2008 – Olympus America Inc. has signed an agreement with Thermo Fisher Scientific to enhance Olympus’ laboratory automation offerings to U.S. customers with a comprehensive open track automation solution for clinical laboratories. The new product offering will complement existing Olympus Lab Automation products including the OLA2500®. The agreement between the […]
Gene Security Network, Inc. (GSN) announced today the introduction of the All Chromosome Aneuploidy Screening test, powered by Parental Support™bioinformatics. This is the first commercially available test to leverage bioinformatics to inform in vitro fertilization (IVF) transfer decisions by identifying potential abnormalities across all 24 chromosomes (aneuploidy) from a single embryonic cell. Test results are […]
Arbor Vita Corporation (AVC), a privately held biopharmaceutical company, today announced a strategic collaboration in women’s health with BD (Becton, Dickinson and Company), a leading global medical technology company. The collaboration and license agreement is initially focused on the development of a commercial diagnostic for cervical cancer, which globally affects more than 500,000 women each […]
QIAGEN N.V. (NASDAQ: QGEN) (FRANKFURT: QIA) today announced the launch of a new test to determine mutations of the K-ras gene. The K-ras gene is mutated in between 35 percent and 45 percent of metastatic colorectal cancer (CRC) patients. Studies have shown that K-ras testing can better define which CRC patients will benefit from treatment […]
India Chosen as First Commercial Market to Demonstrate Test’s Potential for Rapid Uptake OSLO and FOSTER CITY, California, November 10 — DiaGenic ASA (OSL: DIAG) and Applied Biosystems Inc. (NYSE: ABI – News) today announced the launch of BCtect(TM), a blood-based test for early detection of breast cancer. The test searches for a unique gene […]
Test Simultaneously Identifies and Differentiates More Virulent 027 Strain from Common Strains SUNNYVALE, Calif., Nov. 10 — Cepheid (Nasdaq: CPHD – News) today announced the release of Xpert(TM) C. difficile as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. For the first time, European hospitals will have […]
SAN DIEGO–Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and rapid diagnostic products, has entered into an agreement with A. Menarini Diagnostics S.r.l., a division of The Menarini Group, the leading Italian pharmaceutical and diagnostics group, to commercialize CE marked IVD infectious disease kits based on Nanogen’s proprietary MGB technology. The arrangement combines Nanogen’s strength in […]
Signature Genomic Laboratories announced it has made its Genoglyphix® microarray visualization program available to its full-service clients. Previously available only to laboratories that analyze microarray results using Signature research-use-only microarrays in-house, the HIPAA-compliant Genoglyphix service allows users to visualize microarray test results for their patients over a secure online server. For each patient, the Genoglyphix […]
Worldwide license agreement expands the Company’s veterinary assay portfolio and aims to contain future outbreaks of the devastating viral disease Venlo, The Netherlands – November 6, 2008 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) has announced today that it has entered into a worldwide exclusive partnership with the Institute for Animal Health (IAH), […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
